Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda 1 (pembrolizumab), have met their primary endpoints. “We are excited to ...
United States nuclear revival advances as Idaho National Laboratory and startups like Antares and Aalo Atomics push small ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results